ARO-HBV
- Generic Name
- ARO-HBV
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 37
- Registration Number
- NCT05275023
- Locations
- 🇪🇸
Hosp. Univ. Pta. de Hierro Majadahonda, Madrid, Spain
🇬🇧Imperial College London and Imperial College Healthcare NHS Trust, London, United Kingdom
🇫🇷Hopital Beaujon, Clichy, France
A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT05123599
- Locations
- 🇮🇹
Irccs Ospedale Maggiore Di Milano, Milano, Italy
🇳🇿New Zealand Clinical Research, Auckland, New Zealand
🇵🇱ID Clinic, Myslowice, Poland
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT05005507
- Locations
- 🇺🇸
I.D. Care, Inc., Hillsborough, New Jersey, United States
🇪🇸Hosp. Univ. Vall D Hebron, Barcelona, Spain
🇪🇸Hosp. Univ. Infanta Leonor, Madrid, Spain
A Study of JNJ-73763989 in Adult Participants With Renal Impairment
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 29
- Registration Number
- NCT04963738
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04667104
- Locations
- 🇯🇵
Tokyo Medical and Dental University Hospital, Bunkyo Ku, Japan
🇯🇵Osaka University Hospital, Suita-shi, Japan
🇵🇱Przychodnia EuroMediCare Wroclaw Lowiecka, Wroclaw, Poland
A Study of JNJ-73763989 in Healthy Chinese Adult Participants
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT04586439
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, China
A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection
- Conditions
- Hepatitis B
- Interventions
- Drug: PegIFN-alpha-2a (Optional)
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT04585789
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇫🇷Hopital Beaujon, Clichy, France
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
- Conditions
- Hepatitis D, Chronic
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT04535544
- Locations
- 🇯🇵
National Hospital Organization Shikoku Cancer Center, Iizuka-shi, Japan
🇺🇸Stanford University School of Medicine, Redwood City, California, United States
🇺🇸Harvard Medical School Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT04439539
- Locations
- 🇬🇧
Kings College Hospital, London, United Kingdom
🇬🇧Grahame Hayton Unit, London, United Kingdom
🇺🇸Ruane Clinical Research Group Inc, Los Angeles, California, United States
A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 16
- Registration Number
- NCT04208386
- Locations
- 🇩🇪
CRS Clinical Research Services Kiel GmbH, Kiel, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.